OBJECTIVES: This study was performed to elicit ICER threshold range in Korea and to investigate the magnitude of relative influence of main attributes to reimbursement decision. METHODS: This study was based on experts survey using discrete choice experiments (DCE). DCE is stated preference method, in which respondents are requested to express preferences for sets of hypothetical choice alternatives constructed according to experimental design principles. Total 39 respondents (22 from the government or academia and 17 from industry) were responded to this survey among 95 selected experts who were working in pharmacoeconomics field. We identified 6 attributes (disease severity, availability of alternative therapy, burden of disease, ICER, uncertainty of cost-effectiveness ratio and budget impact) which are considered as main decision factors for reimbursement decision. Literatures related to reimbursement decision in Australia, UK, Canada and Korea were comprehensively investigated to elicit these attributes. 18 choice sets having two alternatives were selected using fractional factorial design (FFD). Each coefficient of 6 attributes and probabilities of a recommendation response by ICER range were estimated. RESULTS: Total 1346 observations were analyzed using probit model. 4 attributes (severity, burden, alternative, ICER) significantly influenced on respondents' choice on reimbursement decision (p 0.001). If the disease is severe and rare, the probability of recommending the alternative as cost-effective is higher. The lower ICER, the higher the probability of choosing the alternatives. ICER range threshold from survey results is 70,000,000 KRW approximately. If industry group were excluded in the analysis, the figure reduced to 40,000,000 KRW. CONCLUSIONS: This study showed that severity, burden, alternative, ICER is important factor for reimbursement decision in Korea as well expected. The ICER threshold estimated from this study between the estimators from previous studies. The study design and/or respondent characteristics could affect these figures.
PMC29 IMPACT OF MISSING DATA ON POTENTIAL CONFOUNDERS IN PERINATAL PHARMACOEPIDEMIOLOGIC STUDIES USING ADMINISTRATIVE DATABASES
Bérard A, Nakhai-Pour HR, Kulaga S University of Montreal, Montreal, QC, Canada OBJECTIVES: Administrative databases are increasingly being used in perinatal pharmacoepidemiology. Although such studies have increased statistical power, they are prone to biases due to lack of information on potential confounders. Hence, the objective was to quantify the degree of bias introduced by the lack of data on smoking status and maternal pre-pregnancy weight in the association between gestational exposure to antidepressants and the risk of low birth weight (LBW) infants. METHODS: The Quebec Pregnancy Registry was used to sample a cohort of women who had delivered a liveborn singleton, and answered a self-administered questionnaire on lifestyles during pregnancy and family history. The association between antidepressant use during pregnancy and the risk of LBW was calculated unadjusting for smoking status and maternal pre-pregnancy weight using the Registry data. The association was further estimated adjusting for smoking and maternal pre-pregnancy weight using the questionnaire data. Percent bias in the Registry estimate was calculated using Schneeweiss' method. RESULTS: Overall, the unadjusted estimate (Registry data) for the association between antidepressant use during pregnancy and the risk of LBW was 1.16 (p .05). Adjusting for smoking status resulted in an estimate of 0.99 (p 0.05), and for maternal pre-pregnancy weight, 1.19 (p 0.05). The percent bias introduced by the non-adjustment for smoking and maternal pre-pregnancy weight using only the Registry data was 13%, and did not change the direction of the effect. CONCLUSIONS: Although data on potential confounders are often missing in perinatal pharmacoepidemiologic studies using administrative databases, the bias that results for the non-adjustment does not necessarily invalidate findings.
PMC30 HOW TO GAIN HIGH DATA QUALITY IN A NON-INTERVENTIONAL TRIAL TAKING THE LIVE-COM STUDY AS EXAMPLE
Schön H 1 , Theobald K 2 , Schädlich PK 3 1 CSG mbH, Berlin, Germany, 2 Sanofi-Aventis Germany, Frankfurt, Germany, 3 IGES Institut GmbH, Berlin, Germany OBJECTIVES: The increasing scientificness and complexity of non-interventional studies is facing new operational and quality management aspects to gain high level quality data and results. Therefore it is crucial to implement quality measurements as part of the overall study design. METHODS: A non-interventional, comparative multicenter, representative cross sectional cost evaluation study was conducted (LIVE-COM 1 ). The study retrospectively documented and compared diabetes-specific resource utilisation and patient-reported outcomes (PRO) associated with insulin administration in patients with type-2 diabetes mellitus over six months. The study was performed in accordance with the recommendations to improve quality and transparency of non-interventional studies of the German Association of Research-Based Pharmaceutical Companies and according to Good Epidemiological Practice. A detailed study plan, containing scientific objectives and statistical methods was developed before start of study and approved by the responsible Ethic Committee. In addition a feasibility assessment of the case record forms and PRO-instruments was performed in advance. A total of 4000 randomly selected primary care units were invited to participate in LIVE-COM. Throughout the study a close telephone monitoring with the sites was implemented, also to ensure the collection of the PRO data from the patient. A detailed in-house review of the case record forms, double data entry, query resolutions and source data verification at 10% of the sites was implemented. RESULTS: In total 1731 patients with signed informed consent were included in the study at 138 study centres in Germany. Overall only 1.3% of the documented patient data showed missing values and the validity of the data was high. Only in rare cases imputation algorithms were applied or data were excluded from analyses. CONCLU-SION: The implementation of data quality management procedures and close contact with the study sites can deliver high quality data comparable to clinical studies. 1 Long Acting Insulin Glargine Versus Insulin Detemir Cost Evaluation Comparison.
PMC31 THE MONDRIAAN PROJECT: THE DUTCH HEALTH CARE LANDSCAPE AS A POPULATION LABORATORY
Klungel OH 1 , Rietveld MC 2 , de Groot MC 3 , Stolk RP 4 , Postma MJ 5 , Leufkens HG 1 , Egberts TC 3 , Hövels AM 6 , van de Langerijt L 7 , Hoes AW 3 , Grobbee DE 3 1 Utrecht University, Utrecht, The Netherlands, 2 University Medical Center Utrecht, Utrecht,, The Netherlands, 3 University Medical Center Utrecht, Utrecht, The Netherlands, 4 University Medical Center Groningen, Groningen, The Netherlands, 5 University of Groningen, Groningen, The Netherlands, 6 GlaxoSmithKline The Netherlands, Zeist, The Netherlands, 7 Sanofi-aventis The Netherlands B.V, Gouda, The Netherlands OBJECTIVES: To optimize routine health care databases in The Netherlands for pharmaco-epidemiologic and economic research in order to improve the benefit-risk assessment and the assessment of the value of medicines in daily practice. The gap between pre-clinical pharmaceutical research and clinical and outcomes research hampers optimal benefit-risk assessment and monitoring of new and existing medicines as well as determining their value in daily practice. Although many excellent health care databases are available in The Netherlands for pharmaco-epidemiologic and -economic research, in isolation these data remain scattered, rather inaccessible and cover relatively inadequate population sample sizes and/or are rather limited in detail of the registered information. METHODS: In the first phase we have linked pharmacy records from the National Foundation of Pharmaceutical Statistics (N 12,000,000) on a patient base to several routine health care databases such as the Almere Health Care database (N 160,000), the Utrecht Health Project (N 20,000), and the AGIS claims database (N 1,000,000). To ensure protection of patient privacy, pseudonimisation and linkage was performed through a trusted third party (TTP). A data catalogue has been developed to allow simple queries over the integrated databases which will help in the design of pharmacoepidemiologic studies (incl. sample size calculations, assessment of completeness of data). In the second phase, we will include several other health care and research databases in The Netherlands (Lifelines, Interaction database (IADB), and the Northern GP registration). RESULTS: The proposed research program will deliver a strong, large-scale, high-quality, internationally competitive data platform for innovative pharmaceutical research and provide the tools to improve benefit-risk assessment of medicines. Aging, Death and Birth of Agents is implemented. Parameters can be identified with real population data of Austria provided by "Statistik Austria". Social part. Epidemics can be spread only through direct contact between two agents. Contacts can happen at home, at work, and randomly. Additional rules (f.e. age distribution of people in contact depending on the age of the persons) are defined. Epidemics part. The procedure of the epidemics part is depicting the contact based infections, carrying time and end of illness, including, time and age specific carrying time of special bacterial strains. Extra features for simulation of two or more pathogens in parallel are developed. RESULTS: The concept has been validated using detailed data for serious pneumococcal indicated diseases for Austria. Stability analysis and dependency on starting parameters was examined. Results show stable realistic behavior for single serotype and competing serotypes. CONCLUSIONS: Using this dynamic modeling concept simulation of non linear effects like herd immunity and serotype replacement is possible for testing vaccination strategies. One of the main benefits is that for parameterization and identification no abstract values are used, so objectivity and traceability are assured.
CONCEPTUAL PAPERS & RESEARCH ON METHODS -Modeling Methods

PMC32 MULTI AGENT SIMULATION TECHNIQUES FOR DYNAMIC SIMULATION OF SOCIAL INTERACTION AND SPREAD OF DISEASES WITH DIFFERENT SEROTYPES
PMC33 CRITICAL REVIEW OF ECONOMIC MODELS IN TYPE 2 DIABETES
Yi Y 1 , Bergman G 2 , Burslem K 3 , Philips Z 4 1 Mapi Values, Cheshire, UK, 2 Mapi Values, Houten, The Netherlands, 3 Boehringer Ingelheim Limited, Berkshire, UK, 4 Mapi Values, Macclesfield, UK OBJECTIVES: To identify and critically appraise cost-effectiveness models developed to evaluate type 2 diabetes (T2D) treatments and to assess which types of treatment effects they capture. METHODS: A systematic search was performed in MEDLINE, EMBASE, Centre for Reviews and Dissemination databases at the University of York, and Health Economic Evaluation Database for the period to September 2008. The websites of Health Technology Assessment (HTA) bodies in different countries were also screened for relevant models. For each of the identified original models, details of the structure, data in-and outputs and consistency were extracted and critically appraised using published criteria. RESULTS: 78 articles and 41 HTAs reporting relevant economic evaluations were identified. There were ten models with multiple publications, and a further ten models with one associated publication. The critical review demonstrated that most of the existing models had the same fundamental structure, used similar microsimulation techniques and were based on the same key data sources. However, the process for identification of relevant data and their synthesis, as well as the selection of outcomes was, at times, inconsistent and lacked transparency. The models differed according to which diabetes complications and treatment-related adverse events were captured. For example, just one model incorporated changes in patient weight, despite the fact that weight gain can be a side effect of some treatments, and weight loss a potential benefit of others. CONCLUSIONS: Whilst many economic models exist in T2D, most share common features such as the model type. Identified shortcomings are lack of transparency in data identification and evidence synthesis as well as the selection of the modelled outcomes. Future models should aim to include all relevant treatment outcomes, whether these relate to effects on underlying diabetes and its complications or to short-or long-term side effects of treatment.
PMC34
SEROTYPE-SPECIFIC TRANSMISSION DYNAMICS OF INVASIVE PNEUMOCOCCAL DISEASE AFTER VACCINATION WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
Snedecor SJ 1 , Botteman MF 1 , Strutton DR 2 1 Pharmerit North America LLC, Bethesda, MD, USA, 2 Wyeth Research, Collegeville, PA, USA OBJECTIVES: After the introduction of the 7-valent pneumococcal conjugate vaccine (Prevnar®) in the US, the incidence of invasive pneumococcal disease (IPD) caused by the 7 vaccine serotypes declined dramatically in vaccinated children as well as unvaccinated adults (via herd effect benefit). In 2008, a transmission dynamic equation model was developed to capture direct and indirect vaccination effects. This model accurately predicted the total incidence of IPD (caused by all serotypes) after Prevnar® introduction. This original model was refined in the present analysis to predict the dynamics of IPD caused by specific serotypes. METHODS: The model simulates the acquisition of asymptomatic carriage of pneumococci and the development of fatal and non-fatal IPD among vaccinated and unvaccinated individuals aged 2, 2-4, 5-17, 18-49, 50-64, and 65 years old. Categories of pneumococcal serotypes include PCV7-type (4, 6B, 9V, 14, 18C, 19F, and 23F) and non-PCV7-type (all others). The model was calibrated by approximating serotype-specific US IPD surveillance data from the years 1998-2006. RESULTS: The previous model structure fit the disease incidence caused by the PCV7 serotypes quite well, but was inadequate to predict increases in disease caused by the non-PCV7 serotypes due to serotype replacement. Additionally, the surveillance data showed limited increase in IPD caused by non-PCV7 serotypes in the vaccinated 2-year-old group. A subsequent recalibration and reformulation resulted in a revised model able to replicate closely the observed IPD incidence stratified by pneumococcal serotypes. CONCLUSIONS: The revised model validates the accuracy of the original model to replicate the incidence of IPD caused by PCV7 serotypes and may be used to predict the future incidence of disease given the increases in IPD caused by non-PCV7 serotypes. Patients' movements between these disease states defined 17 probability transitions to be estimated. The model was based on data from the Régie de l'assurance maladie du Québec and Med-Echo databases. All individuals aged 0-60 years with a newly diagnosis of schizophrenia between 1998 to 2006 were first identified by ICD-9 codes. Using this data, 5 Cox proportional hazard models for competing risks were used to estimate the 17 probabilities of transition. Validation was conducted by comparing the model's probability transitions' predictions with the published literature. RESULTS: A total of 12,754 individuals were identified as newly diagnosed patients with schizophrenia. After the FE of schizophrenia, 69.8% of patients passed in LDS, 11.2% in HDS, 1% in death state and 18% in Well state. The mean transition probabilities after one year of follow-up were: FE to Well at 0.28 ( SD 0.10), FE to HDS at 0.11 ( 0.05), FE to LDS at 0.60 ( 0.08) and respectively FE to Death at 0.01 ( 0.01). The corresponding values were similar to those obtained from other published models. CONCLUSIONS: This model is the first Canadian model incorporating transition probabilities adjusted for individual risk factors profiles using Canadian data. Future applications will include pricing and cost-effectiveness of new therapies for schizophrenia.
PMC36 CREATING NATIONAL WEIGHTS FOR PRIVATE INSURANCE DATABASE
Baser O 1 , Wang L 2 1 University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2 STATinMED Research, Ann Arbor, MI, USA OBJECTIVES: To create national weights to project a private database to the US insured population controlling not only for socio-demographic factors but also health status. METHODS: The Medicare Expenditure Survey was used as the basis of adjustment methodology. First, we subset the data source to the study population, then used multivariate logistic regression to construct demographics and case-mix based weights that were applied to make the data similar to the national sample. Propensity Score Matching and Raking algorithm is combined to create the adjusted weights. The socioeconomic characteristics included in the model were the age of the head of the household, percentage of the patients who were female, race, geographic region and income level. We derived two variables to capture general health status of the member. First, Charlson Index scores were generated to capture the level and burden of comorbidity. Secondly, we created an indicator variable to represent patients with chronic conditions. This variable was derived by convening two physician panels to review all medical conditions reported by the survey sample. RESULTS: Private data were more likely to be male, white, older, and chronic (p 0.0000). Adjusted weight values for the Commercial group ranged from 13.47 to 26.39 with median 16.35. The projected US population by private database and MEPS data were similar in terms of socioeconomic and clinical categories. As an outcomes measure, the predicted annual statin users from private data was 6,973,034. Statin users are predicted as 6,709,438 using MEPS data with MEPS weights. CONCLUSIONS: National projection of a private database requires adjustment from not only demographic factors but also case-mix differences related to health status. The created weights successfully balanced the population in terms of co-morbid conditions and chronic conditions as well as demographic factors.
PMC37
COMPARISON OF RISK ADJUSTMENT MODELS IN OUTCOMES RESEARCH
Baser O 1 , Gust C 2 , Dysinger A 2 , Yuce H 3 , Akin C 1 , Wang L 2 1 University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2 STATinMED Research, Ann Arbor, MI, USA, 3 STATinMED Research and The City University of New York, Brooklyn, NY, USA OBJECTIVES: Matching and regression analysis are two approaches to estimate average treatment effect. Different matching techniques provide different results. Moreover, matching cannot control for unobserved bias. Using ProbChoice algorithm and Rosenbaum bounding approach, we aim to show how to choose strongly unmeasured variable must influence the selection process to undermine the implication of matching and regression analysis. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Data is used for the analysis. For each patient, their hospital of care and associated hospital volume is computed. Patients in the high and low volume hospitals are matched in seven different ways in terms of demographic and clinical characteristics. Treatment costs are compared. The best technique is chosen by Prob-Choice algorithm. Rosenbaum bonds estimated and Mantel and Haenszel test statistics is calculated to provide evidence on the degree to which any significance results hinge on unconfoundedness assumption. RESULTS: A volume cohort was constructed consisting of 19,375 female SEER-Medicare patients, aged 65 , suffering an in situ and/or invasive breast cancer during 2003-2005 with surgical treatment performed at 567 hospitals. Mahalobis matching is the one who created the best balanced comparable sets. After the matching, samples were similar in terms of race, comorbidity and adjuvant therapies. Under the assumption of no hidden bias, costs were lower of the high volume hospitals. (p 0.000). Results were insensitive to a bias that would double the odds of being treated high volume hospitals but sensitive to a bias that would triple the odds. CONCLUSIONS: There exist several matching techniques and the results depend the type of matching chosen. One needs to chose the technique best suitable for the data. Rosenbaum bonds provides evidence on sensitivity of the estimated results with respect to unobservable factors that is not controlled by propensity score matching.
